1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015; 386(10003):1546–1555.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014; 73(1):62–68.
![crossref](/image/icon/bnr_ref_cross.gif)
3. Aithal GP. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol. 2011; 7(3):139–150.
![crossref](/image/icon/bnr_ref_cross.gif)
4. Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford). 2012; 51:Suppl 6. vi37–vi43.
![crossref](/image/icon/bnr_ref_cross.gif)
5. Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg JD, Kavanaugh A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis. 2010; 69(1):43–47.
![crossref](/image/icon/bnr_ref_cross.gif)
6. Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. 2011; 46(4):556–564.
![crossref](/image/icon/bnr_ref_cross.gif)
7. Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol. 2012; 31(8):1169–1175.
![crossref](/image/icon/bnr_ref_cross.gif)
8. Ryu HH, Lee EY, Shin K, Choi IA, Lee YJ, Yoo B, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases. Clin Rheumatol. 2012; 31(6):931–936.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2011; 21(1):16–23.
![crossref](/image/icon/bnr_ref_cross.gif)
10. Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011; 70(10):1719–1725.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Burton MJ, Curtis JR, Yang S, Chen L, Singh JA, Mikuls TR, et al. Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. Arthritis Res Ther. 2015; 17(1):136.
![crossref](/image/icon/bnr_ref_cross.gif)
12. Shin K, Jang H, Jang WM, Lee JS, Song YW. Treatment of rheumatoid arthritis patients with chronic hepatitis B: analysis of Korean National Health Insurance claims data. J Rheum Dis. 2013; 20(1):24–29.
![crossref](/image/icon/bnr_ref_cross.gif)
13. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000; 27(1):261–263.
14. Balsa A, Carmona L, González-Alvaro I, Belmonte MA, Tena X, Sanmartí R, et al. Value of disease activity score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol. 2004; 31(1):40–46.
15. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38(1):44–48.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45(2):507–539.
![crossref](/image/icon/bnr_ref_cross.gif)
17. Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009; 49(5):Suppl. S156–S165.
![crossref](/image/icon/bnr_ref_cross.gif)
18. Zou CJ, Zhu LJ, Li YH, Mo YQ, Zheng DH, Ma JD, et al. The association between hepatitis B virus infection and disease activity, synovitis, or joint destruction in rheumatoid arthritis. Clin Rheumatol. 2013; 32(6):787–795.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Kim PS, Ho GY, Prete PE, Furst DE. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res (Hoboken). 2012; 64(8):1265–1268.
![crossref](/image/icon/bnr_ref_cross.gif)
20. Ming-Xu H, Chen M, Cai Y, Yan-Jia H. Clinical outcomes of low-dose leflunomide for rheumatoid arthritis complicated with hepatitis B virus carriage and safety observation. Pak J Med Sci. 2015; 31(2):320–324.
![crossref](/image/icon/bnr_ref_cross.gif)
21. Balabanova RM, Shekshina EV, Kozlov LV. Immunological features of rheumatoid arthritis in patients infected with viruses of hepatitis B, C and in patients with cryoglobulinemia. Ter Arkh. 2004; 76(11):74–77.
22. Pincus T. Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2008; 66(3):216–223.
23. Eberl DR, Fasching V, Rahlfs V, Schleyer I, Wolf R. Repeatability and objectivity of various measurements in rheumatoid arthritis. A comparative study. Arthritis Rheum. 1976; 19(6):1278–1286.
![crossref](/image/icon/bnr_ref_cross.gif)
24. Lassere MN, van der Heijde D, Johnson KR, Boers M, Edmonds J. Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials. J Rheumatol. 2001; 28(4):892–903.
25. Pincus T, Amara I, Segurado OG, Bergman M, Koch GG. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol. 2008; 35(2):201–205.
26. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59(6):762–784.
![crossref](/image/icon/bnr_ref_cross.gif)
27. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 64(5):625–639.
![crossref](/image/icon/bnr_ref_cross.gif)
28. Habib GS. Systemic effects of intra-articular corticosteroids. Clin Rheumatol. 2009; 28(7):749–756.
![crossref](/image/icon/bnr_ref_cross.gif)
29. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015; 148(1):221–244.e3.
![crossref](/image/icon/bnr_ref_cross.gif)
30. Chen MH, Chen MH, Liu CY, Tsai CY, Huang DF, Lin HY, et al. Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment. J Infect Dis. 2017; 215(4):566–573.
![crossref](/image/icon/bnr_ref_cross.gif)
31. Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis. 2016; 19(5):470–475.
![crossref](/image/icon/bnr_ref_cross.gif)
32. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017; 152(6):1297–1309.
![crossref](/image/icon/bnr_ref_cross.gif)
33. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004; 90(7):1306–1311.
![crossref](/image/icon/bnr_ref_cross.gif)
34. Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis. 2013; 33(2):167–177.
![crossref](/image/icon/bnr_ref_cross.gif)
35. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003; 125(6):1742–1749.
![crossref](/image/icon/bnr_ref_cross.gif)
36. Long M, Jia W, Li S, Jin L, Wu J, Rao N, et al. A single-center, prospective and randomized controlled study: can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat. 2011; 127(3):705–712.
![crossref](/image/icon/bnr_ref_cross.gif)
37. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3):661–662.
![crossref](/image/icon/bnr_ref_cross.gif)
38. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1):167–185.
39. Korean Association for the Study of the Liver. KASL clinical practice guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012; 18(2):109–162.
40. Mo YQ, Liang AQ, Ma JD, Chen LF, Zheng DH, Schumacher HR, et al. Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice. BMC Musculoskelet Disord. 2014; 15(1):449.
![crossref](/image/icon/bnr_ref_cross.gif)